Probi to launch gut and immune health products in Belarus with AlenMed under the Probi brand
Probi has signed a distribution agreement with AlenMed Promotion SIA, based in Riga, Latvia for the distribution of Probi Digestis® and Probi Defendum® in Belarus through their representative office in Belarus from Q1 2014.
“AlenMed is an international team of experts in the field of marketing and distribution of medical products in Belarus and in the CIS Region. Currently, the company is closely cooperating with companies such as Merck Serono, Axellus, Cook Medical, Certmedica and Bioclin and is going to be an important partner for Probis expansion in the area in the coming years”, says Gun-Britt Fransson, Interim CEO of Probi.
Probi Digestis® is based on Lactobacillus plantarum 299v (DSM 9843), which targets bloating, gas formation and pain, common symptoms that are sometimes mild or temporary but often more severe and diagnosed as IBS. Probi Defendum® is based on the combination of two probiotic strains, Lactobacillus plantarum HEAL9 (DSM 15312) and Lactobacillus paracasei 8700:2 (DSM 13434). This probiotic mix has been proven in large clinical studies to prevent colds, significantly reduce cold symptoms and shorten cold periods.
Probi Digestis® and Probi Defendum®will be registered and launched under the Probi brand with emphasis on Probi’s high quality probiotic ingredients. Both products will be sold by AlenMed Promotion’s field force targeting GPs and Gastroenterologists (Probi Digestis®) and GPs and Pediatricians (Probi Defendum®) as well as to consumers via retail drug stores and pharmacies.
The information is such that Probi AB must disclose in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act.
FOR FURTHER INFORMATION, CONTACT:
Gun-Britt Fransson, Interim CEO, Probi, phone +46 46 286 89 74 or mobile +46 705 95 73 27, e-mail: gun-britt.fransson@probi.se
Niklas Bjärum, Vice President Marketing & Sales, Probi, phone +46 46 286 89 67 or mobile +46 705 38 88 64, e-mail: niklas.bjarum@probi.se
ABOUT PROBI
Probi is a leading player in probiotic research and development of effective and well-documented probiotics. The research areas are: the gastrointestinal tract, immune system, metabolic syndrome and stress and recovery. Probi’s customers are leading companies in the Functional Food and Consumer Healthcare segments. Total income for 2012 was MSEK 100.4. Probi’s share is listed on Nasdaq OMX Stockholm, Small Cap. Probi has approximately 5,000 shareholders. Read more on www.probi.se.
ABOUT ALENMED PROMOTION SIA
AlenMed Promotion SIA was established in 2005 in Latvia, Riga and the Representative Office was set up in Belarus given the country’s strategic location and proximity to emerging CIS markets. Since its foundation, AlenMed has been focusing on innovation, professionalism, and custom-tailored approach. Today, the team numbers 37 professionals with many years’ experience in medicine, medical products marketing and distribution business, finance, international relations and the company is consistently growing offering flexibility of supplies, prompt registration and product promotion services.
Tags: